Amgen | Pharmatell

top of page

PHARMATELL horizontal (1).png

PharmaTell Pharmaceutical and Healthcare Strategic Intelligence.png

Eyes on Pharma

Check-out What Intel Caught our Eye

Office buildings seen through a magnifying glass

Office buildings seen through a magnifying glass

Patent Expiries on the Horizon

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

Apr 82 min read

Medical professional looking at a screen with an overlay of scientific images.

Medical professional looking at a screen with an overlay of scientific images.

Bolstering Pipelines & Other BioPharma Current Events

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

Feb 207 min read

Eyes on 3Q24 Financial Results

Eyes on 3Q24 Financial Results

Eyes on 3Q24 Financial Results

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

Dec 11, 202416 min read

Eyes on Sanofi, Regeneron, Novo Nordisk, and Pfizer

Eyes on Sanofi, Regeneron, Novo Nordisk, and Pfizer

Eyes on Sanofi, Regeneron, Novo Nordisk, and Pfizer

We've had Eyes On some of the recent deals, results, and investor actions. Check out the happenings at Sanofi/Opella, Pfizer, Regeneron, and

Nov 17, 20244 min read

Eyes on BMS, Pfizer, & Amgen

Eyes on BMS, Pfizer, & Amgen

Eyes on BMS, Pfizer, & Amgen

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

Oct 5, 20246 min read

bottom of page